Last reviewed · How we verify
Glucion 5%
Glucion 5%, marketed by Niels Van Regenmortel, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established position to generate consistent revenue. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Glucion 5% |
|---|---|
| Sponsor | Niels Van Regenmortel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- TOnicity of Perioperative Maintenance SoluTions (PHASE4)
- Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucion 5% CI brief — competitive landscape report
- Glucion 5% updates RSS · CI watch RSS
- Niels Van Regenmortel portfolio CI